Global Bleeding Disorders Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

 Bleeding Disorders Treatment Market Size

• The global bleeding disorders treatment market size was valued at USD 11.55 billion in 2024 and is expected to reach USD 23.53 billion by 2032, at a CAGR of 9.30% during the forecast period
• This growth is driven by factors such as the rising prevalence of hemophilia and other bleeding disorders, increasing adoption of advanced therapies, and improved access to diagnostic and treatment facilities globally

Bleeding Disorders Treatment Market Analysis

• The bleeding disorders treatment market focuses on therapies that manage conditions such as hemophilia A and B, von Willebrand disease, and other rare clotting factor deficiencies by improving clot formation and reducing bleeding episodes
• The market growth is primarily driven by increasing diagnosis rates, improved access to healthcare in developing regions, and advancements in recombinant and non-factor therapies
• North America is expected to dominate the bleeding disorders treatment market with a market share of 40.5%, due to advanced healthcare systems, high diagnosis rates, and the strong presence of leading pharmaceutical and biotechnology companies
• Asia-Pacific is expected to be the fastest growing region in the bleeding disorders treatment market with a market share of 24.2%, during the forecast period due to increasing awareness, expanding healthcare infrastructure, and rising government initiatives for rare disease management
• Hemophilia A segment is expected to dominate the market with a market share of 56.22% due to its higher global prevalence compared to other bleeding disorders and the widespread availability of targeted therapies, particularly recombinant factor VIII

Report Scope and Bleeding Disorders Treatment Market Segmentation      

Bleeding Disorders Treatment Market Trends

“Shift Toward Gene Therapy and Long-Acting Treatments”

• One prominent trend in the bleeding disorders treatment market is the growing focus on gene therapy and long-acting factor replacement therapies aimed at providing sustained relief and potential cures for conditions such as hemophilia
• These innovative treatments reduce the frequency of infusions and enhance patients' quality of life by maintaining stable clotting factor levels over extended periods 
  • For instance, recent approvals of gene therapies for hemophilia A and B demonstrate promising long-term results, reducing or eliminating the need for regular prophylactic treatments
• This shift toward advanced therapeutic modalities is reshaping treatment protocols, improving patient outcomes, and driving significant investment in bleeding disorder research and development

Bleeding Disorders Treatment Market Dynamics

Driver

“Rising Prevalence and Early Diagnosis of Bleeding Disorders”

• The increasing global prevalence of bleeding disorders such as hemophilia A, hemophilia B, and von Willebrand disease is a major driver for the market, leading to higher demand for effective treatment solutions
• Advancements in diagnostic techniques and greater awareness have led to earlier detection, enabling timely intervention and management of these conditions
• Governments and health organizations are expanding screening programs and access to therapies, especially in developing regions, contributing to market growth

For instance,

• In a 2022 report by the World Federation of Hemophilia, over 1.2 million people globally are estimated to have bleeding disorders, with more than 400,000 having hemophilia, many of whom remain undiagnosed, emphasizing the need for enhanced treatment availability 
• As the burden of bleeding disorders continues to rise globally, the need for accessible, advanced, and sustained treatment options is fueling significant growth in the bleeding disorders treatment market

Opportunity

“Emergence of Gene Therapy and Personalized Medicine”

• The development and approval of gene therapies offer a transformative opportunity in the treatment of bleeding disorders, particularly for hemophilia A and B, by potentially providing long-term or permanent solutions
• Gene therapy can reduce or eliminate the need for frequent factor replacement therapy by enabling the body to produce its own clotting factors, thus significantly improving patient outcomes and quality of life
• In addition, advancements in personalized medicine allow for tailored treatment approaches based on individual genetic profiles, enhancing efficacy and minimizing adverse effects

For instance,

• In June 2023, the U.S. FDA approved the first gene therapy for adults with hemophilia A, marking a major milestone in the treatment landscape. The therapy delivers a functional copy of the defective gene, enabling sustained clotting factor production and significantly reducing bleeding episodes 
• The growing investment in gene therapy research and the shift toward individualized treatment strategies present immense opportunities for innovation and expansion in the bleeding disorders treatment market

Restraint/Challenge

“High Cost of Advanced Therapies and Limited Access in Low-Income Regions”

• The high cost of bleeding disorder treatments, especially advanced options such as recombinant factors, extended half-life products, and gene therapies, remains a significant challenge for market expansion
• These therapies often require lifelong administration or involve substantial one-time expenses, placing a heavy financial burden on healthcare systems and patients, particularly in developing and underdeveloped regions
• Limited insurance coverage and lack of reimbursement policies in some countries further restrict patient access to effective treatment options

For instance,

• In 2023, the National Hemophilia Foundation reported that the average annual treatment cost for severe hemophilia A patients in the U.S. can exceed $300,000, while gene therapies are priced at over USD 2 million per dose, making affordability a critical issue 
• As a result, many patients in low- and middle-income countries remain untreated or undertreated, creating disparities in care and hindering the overall growth and equitable penetration of the bleeding disorders treatment market

Bleeding Disorders Treatment Market Scope

The market is segmented on the basis of drug type, disease type, distribution type, and end user

In 2025, the hemophilia A is projected to dominate the market with a largest share in disease type segment

The hemophilia A segment is expected to dominate the bleeding disorders treatment market with the largest share of 56.22% in 2025 due to its higher global prevalence compared to other bleeding disorders and the widespread availability of targeted therapies, particularly recombinant factor VIII. Continuous advancements in treatment options, including long-acting and gene therapies, further drive this segment’s growth. Moreover, strong awareness and screening initiatives contribute to increased diagnosis and management of Hemophilia A.

The recombinant coagulation factor concentrates is expected to account for the largest share during the forecast period in drug type market

In 2025, the recombinant coagulation factor concentrates is expected to dominate the market with the largest market share of 40.5% due to its enhanced safety profile, eliminating the risk of blood-borne infections associated with plasma-derived products. These therapies offer consistent potency, reduced immunogenicity, and improved patient outcomes. In addition, ongoing advancements in recombinant technology and increasing adoption in both developed and emerging markets support this segment’s growth.

Bleeding Disorders Treatment Market Regional Analysis

“North America Holds the Largest Share in the Bleeding Disorders Treatment Market”

• North America dominates the bleeding disorders treatment market with a market share of estimated 40.5%, driven, by advanced healthcare systems, high diagnosis rates, and the strong presence of leading pharmaceutical and biotechnology companies
• U.S. holds a market share of 60.5%, due to favorable reimbursement frameworks, increased availability of advanced therapies, and robust research and development activities in gene and recombinant therapies
• Continuous regulatory support and public awareness campaigns have led to early diagnosis and timely treatment, further strengthening market growth in the region
• In addition, the high healthcare spending, along with strong patient advocacy organizations and hemophilia treatment centers, continues to fuel the demand for bleeding disorder therapies across North America

“Asia-Pacific is Projected to Register the Highest CAGR in the Bleeding Disorders Treatment Market”

• Asia-Pacific is expected to witness the highest growth rate in the bleeding disorders treatment market with a market share of 24.2%, driven by increasing awareness, expanding healthcare infrastructure, and rising government initiatives for rare disease management
• Countries such as China, India, and South Korea are emerging as key growth markets due to improving diagnostic capabilities, increasing access to treatment, and rising prevalence of undiagnosed bleeding disorders
• Japan, with its advanced biotechnology sector and strong focus on rare disease therapies, continues to invest heavily in innovative treatment approaches, making it a crucial market for bleeding disorder therapies
• India is projected to register the highest CAGR in the bleeding disorders treatment market, driven by growing patient awareness, expanding insurance coverage, and rising investment in rare disease research and access to advanced therapies

Bleeding Disorders Treatment Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• CSL (Australia)
• Novo Nordisk A/S (Denmark)
• Pfizer Inc. (U.S.)
• Takeda Pharmaceutical Company Limited (Japan)
• Octapharma AG (Switzerland)
• Biogen (U.S.)
• Sanofi (France)
• Grifols, S.A. (Spain)
• Kedrion (Italy)
• BioMarin (U.S.)
• Spark Therapeutics, Inc. (U.S.)
• uniQure N.V. (Netherlands)
• Genentech, Inc. (U.S.)
• Aptevo Therapeutics (U.S.)
• Alnylam Pharmaceuticals, Inc. (U.S.)
• Freeline Therapeutics Holdings plc (U.K.)
• Sangamo Therapeutics (U.S.)
• Catalyst Biosciences, Inc. (U.S.)
• Swedish Orphan Biovitrum AB (Sweden)
• Bayer AG (Germany)

Latest Developments in Global ophthalmic Market

• In March 2025, The U.S. FDA approved Qfitlia (fitusiran), the first and only RNA interference (RNAi) therapeutic for the treatment of hemophilia A and B, including patients with or without inhibitors. This approval marks a significant advancement in the treatment options available for individuals with these conditions
• In February 2025, Pfizer announced the cessation of global development and commercialization of its hemophilia B gene therapy, Beqvez. The decision was attributed to limited demand from patients and clinicians, reflecting broader challenges in the adoption of gene therapies within the hemophilia treatment landscape
• In December 2024, The U.S. Food and Drug Administration approved Novo Nordisk's Alhemo, a subcutaneous treatment designed to prevent or reduce bleeding episodes in hemophilia patients aged 12 years and older who have developed inhibitors against clotting factor replacements. This approval offers a new therapeutic option for patients with limited treatment choices due to the presence of inhibitors
• In June 2024, BioMarin Pharmaceutical Inc. presented new Phase 3, four-year data at the International Society on Thrombosis and Haemostasis 2024 Congress, underscoring the long-term safety and efficacy of ROCTAVIAN (valoctocogene roxaparvovec-rvox) in adults with severe hemophilia A. The data demonstrated durable and sustained bleed control and Factor VIII expression maintained four years post-infusion.
• In March 2021, CSL Behring announced a donation of 500 million international units (IUs) of coagulation factor therapy to the World Federation of Hemophilia (WFH) in an effort to promote reliable access to treatment for bleeding disorders, including hemophilia, across more than 60 developing countries. This donation is part of CSL Behring's ongoing commitment to support the WFH Humanitarian Aid Program 

SKU-10125